AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17059437 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (200 mg p.o.)
Number of subjects: 12
Study 17059437 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 14564321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 0
Study 14564321 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 0
Study 10964333 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial group intervention (6-week structured program including health education, coping skills training, stress management, and psychologic support)
Number of subjects: 151
Study 10964333 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 151
Study 8985780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection (ICI) of 20 micrograms/mL PGE1
Number of subjects: 34
Study 8985780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection (ICI) of 25 micrograms/mL PGE1
Number of subjects: 34
Study 8985780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail containing 20 micrograms PGE1 plus 0.5 mg/mL phentolamine
Number of subjects: 34
Study 8985780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail containing 25 micrograms PGE1 plus 0.5 mg/mL phentolamine
Number of subjects: 34
Study 1297297 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg/90 minutes; 10 mg bolus + 90 mg/90 minutes)
Number of subjects: 50
Study 1297297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1297297 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 50
Study 6342151 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic duct drainage
Number of subjects: 11
Study 6342151 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 11
Study 31146534 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long Acting (RPV LA) 1,200 mg
Number of subjects: 12
Study 29718715 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (bup/nal) treatment
Number of subjects: 133
Study 29718715 — intervention group
Group type: COMPARATOR
Intervention: Out-of-bup/nal-treatment group
Number of subjects: 133
Study 27142044 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine dihydrochloride (OCT)
Number of subjects: 110
Study 27142044 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride (BAC)
Number of subjects: 110
Study 27142044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (OCT and BAC)
Number of subjects: 110
Study 25310185 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan+5-fluorouracil/leucovorin (IFL)
Number of subjects: 1264
Study 25310185 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin (FU/LV)
Number of subjects: 1264
Study 22956348 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH supplemented by 100 IU hCG
Number of subjects: 73
Study 22956348 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH alone
Number of subjects: 73
Study 22956348 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH supplemented by 200 IU hCG
Number of subjects: 73
Study 19423612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarette
Number of subjects: 0
Study 19423612 — intervention group
Group type: COMPARATOR
Intervention: Denicotinised cigarette
Number of subjects: 0
Study 19423612 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-abstinent condition
Number of subjects: 0
Study 19423612 — intervention group
Group type: COMPARATOR
Intervention: Abstinent condition
Number of subjects: 0
Study 17852781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity)
Number of subjects: 177
Study 17852781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 177
Study 17852781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 11704083 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (two doses of 400 microg taken 2 h apart)
Number of subjects: 1168
Study 11704083 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (one dose of 800 microg)
Number of subjects: 1168
Study 9231214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin, 15 mg/kg/d for 2 days
Number of subjects: 107
Study 9231214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin, 10 mg/kg/d for 3 days
Number of subjects: 107
Study 9231214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid resistant strains of S. typhi
Number of subjects: 107
Study 9231214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid sensitive isolates of S. typhi
Number of subjects: 107
Study 8430925 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms
Number of subjects: 12
Study 8430925 — intervention group
Group type: COMPARATOR
Intervention: Procaterol 25 micrograms
Number of subjects: 12
Study 3120440 — intervention group
Group type: EXPERIMENTAL
Intervention: Partusisten long term tocolysis
Number of subjects: 0
Study 3120440 — intervention group
Group type: COMPARATOR
Intervention: Ethanol short term tocolysis
Number of subjects: 0
Study 31167545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based intervention
Number of subjects: 0
Study 31167545 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reappraisal-based intervention
Number of subjects: 0
Study 29580298 — intervention group
Group type: EXPERIMENTAL
Intervention: Submental liposuction
Number of subjects: 20
Study 29580298 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 20
Study 27765714 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized functional restoration incorporating advice (10 sessions)
Number of subjects: 54
Study 27765714 — intervention group
Group type: COMPARATOR
Intervention: Guideline‐based advice alone (2 sessions)
Number of subjects: 54
Study 26513847 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based oral care training program
Number of subjects: 94
Study 26513847 — intervention group
Group type: COMPARATOR
Intervention: Routine oral care education with swabs (Control)
Number of subjects: 94
Study 23680334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering of antihypertensive medications over 3 weeks (week 1: reduction by 25%-50%; week 2: 50%-75%; week 3: off)
Number of subjects: 53
Study 23680334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering of antihypertensive medications
Number of subjects: 53
Study 21537968 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual presentation of action words
Number of subjects: 0
Study 21537968 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory presentation of action words
Number of subjects: 0
Study 21537968 — intervention group
Group type: COMPARATOR
Intervention: Control words (visual)
Number of subjects: 0
Study 21537968 — intervention group
Group type: COMPARATOR
Intervention: Control words (auditory)
Number of subjects: 0
Study 18291188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonewax
Number of subjects: 400
Study 18291188 — intervention group
Group type: COMPARATOR
Intervention: Nonwax
Number of subjects: 400
Study 16540959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (10 microg.kg.min, n = 8)
Number of subjects: 16
Study 16540959 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (n = 8)
Number of subjects: 16
Study 12792318 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 58
Study 12792318 — intervention group
Group type: COMPARATOR
Intervention: Expectation treatment (control)
Number of subjects: 58
Study 10739490 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild soap wash with subsequent alcohol-based rinse for degerming
Number of subjects: 16
Study 10739490 — intervention group
Group type: COMPARATOR
Intervention: Traditional antiseptic wash with chlorhexidine-containing detergent
Number of subjects: 16
Study 8776917 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1397914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleet (hypertonic sodium phosphate) enema
Number of subjects: 66
Study 1397914 — intervention group
Group type: COMPARATOR
Intervention: Water enema
Number of subjects: 66
Study 1397914 — intervention group
Group type: COMPARATOR
Intervention: Golytely (polyethylene glycol electrolyte lavage solution) enema
Number of subjects: 66
Study 31710382 — intervention group
Group type: EXPERIMENTAL
Intervention: SWEEPS
Number of subjects: 30
Study 31710382 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPS
Number of subjects: 30
Study 31710382 — intervention group
Group type: EXPERIMENTAL
Intervention: UAI
Number of subjects: 30
Study 29708441 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft fixation with in situ blood coagulum (Group 2)
Number of subjects: 30
Study 29708441 — intervention group
Group type: COMPARATOR
Intervention: Autograft fixation with 10/0 nylon sutures (Group 1)
Number of subjects: 30
Study 29708441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 27029851 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000/200 mg of amoxicillin/clavulanate intravenously
Number of subjects: 266
Study 27029851 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of amoxicillin by mouth
Number of subjects: 266
Study 27029851 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of clindamycin by mouth
Number of subjects: 266
Study 27029851 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of azithromycin by mouth
Number of subjects: 266
Study 27029851 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 266
Study 24285687 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg of anthocyanins twice daily for 24 weeks
Number of subjects: 122
Study 24285687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 22966824 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (scaling, root planing, and oral hygiene instructions)
Number of subjects: 317
Study 22966824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 317
Study 22966824 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 317
Study 19921083 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg daily)
Number of subjects: 20
Study 19921083 — intervention group
Group type: COMPARATOR
Intervention: Control (no alendronate)
Number of subjects: 20
Study 19045965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 123
Study 19045965 — intervention group
Group type: COMPARATOR
Intervention: Maintenance antidepressant medication (m-ADM)
Number of subjects: 123
Study 17145251 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapeutic tinzaparin subcutaneously once daily for 3 months
Number of subjects: 200
Study 17145251 — intervention group
Group type: COMPARATOR
Intervention: Usual care long-term vitamin-K-antagonist therapy for 3 months
Number of subjects: 200
Study 17145251 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapeutic tinzaparin
Number of subjects: 200
Study 17145251 — intervention group
Group type: COMPARATOR
Intervention: Usual care long-term vitamin-K-antagonist therapy
Number of subjects: 200
Study 17145251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 14687502 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 U/0.5 ml/dose of Healive vaccine
Number of subjects: 85
Study 14687502 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/1.0 ml/dose of Healive vaccine
Number of subjects: 85
Study 10874279 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, high-intensity exercise training for 8 weeks
Number of subjects: 25
Study 10874279 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained patients)
Number of subjects: 25
Study 9013098 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral oestrogen therapy (polyestradiol phosphate 240 mg i.m. every month)
Number of subjects: 10
Study 9013098 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy (surgical castration)
Number of subjects: 10
Study 1327850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline
Number of subjects: 6
Study 1327850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3901372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin plus Clindamycin
Number of subjects: 112
Study 3901372 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin plus Placebo
Number of subjects: 112
Study 30503052 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 83
Study 30503052 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intervention Group (CIG)
Number of subjects: 83
Study 29878102 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesiologist-directed sedation (ADS)
Number of subjects: 1242
Study 29878102 — intervention group
Group type: COMPARATOR
Intervention: Proceduralist-directed sedation (PDS)
Number of subjects: 1242
Study 27570988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with pharmacist review of chronic medication according to STOPP‐START criteria; recommendations sent to Primary Care Physician.
Number of subjects: 665
Study 27570988 — intervention group
Group type: COMPARATOR
Intervention: Control arm receiving standard of care without systematic review of adequacy to STOPP‐START criteria.
Number of subjects: 665
Study 25105567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (1mA) during treadmill training
Number of subjects: 24
Study 25105567 — intervention group
Group type: COMPARATOR
Intervention: Placebo tDCS during treadmill training
Number of subjects: 24
Study 25105567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (1mA)
Number of subjects: 24
Study 22364258 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 70
Study 22364258 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 70
Study 20827560 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based general anesthesia
Number of subjects: 210
Study 20827560 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-based conventional anesthesia
Number of subjects: 210
Study 18155216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% sodium hyaluronate solution
Number of subjects: 140
Study 18155216 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 140
Study 15991510 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg hyperbaric ropivacaine + 10 microg fentanyl
Number of subjects: 37
Study 12182261 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 280
Study 12182261 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg once daily)
Number of subjects: 280
Study 10427944 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LASA (categorical linear analogue scale)
Number of subjects: 26
Study 10427944 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish instrument (developed by Glimelius et al.)
Number of subjects: 26
Study 10427944 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LASA and Swedish instrument (global dimension)
Number of subjects: 26
Study 8749883 — intervention group
Group type: EXPERIMENTAL
Intervention: Early warning signs (EWS) of impending relapse
Number of subjects: 0
Study 8749883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical action based on EWS
Number of subjects: 0
Study 8749883 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminology usage
Number of subjects: 0
Study 1851071 — intervention group
Group type: EXPERIMENTAL
Intervention: [2H5]phenylalanine method
Number of subjects: 6
Study 1851071 — intervention group
Group type: EXPERIMENTAL
Intervention: [13C]leucine method (primary pool)
Number of subjects: 6
Study 1851071 — intervention group
Group type: EXPERIMENTAL
Intervention: [13C]leucine method (reciprocal pool)
Number of subjects: 6
Study 1851071 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 6
Study 1851071 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin withdrawal
Number of subjects: 6
Study 7009311 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic variceal obliteration
Number of subjects: 116
Study 7009311 — intervention group
Group type: COMPARATOR
Intervention: Transhepatic sclerotherapy
Number of subjects: 116
Study 7009311 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up portography
Number of subjects: 116
Study 30113919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic pants (BIO)
Number of subjects: 20
Study 31207854 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group-based integrative cognitive remediation (n=25)
Number of subjects: 49
Study 31207854 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (n=24)
Number of subjects: 49
Study 28619613 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental photodynamic therapy (PDT) in one-visit treatment
Number of subjects: 24
Study 28619613 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental photodynamic therapy (PDT) in two-visit treatment
Number of subjects: 24
Study 28619613 — intervention group
Group type: COMPARATOR
Intervention: Chemo-mechanical preparation (CMP) alone in two-visit treatment
Number of subjects: 24
Study 28619613 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental photodynamic therapy (PDT)
Number of subjects: 24
Study 25425224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 51
Study 25425224 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 51
Study 24816724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab, capecitabine, and irinotecan
Number of subjects: 146
Study 22933048 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of olanzapine (10 mg)
Number of subjects: 24
Study 22933048 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of olanzapine (10 mg)
Number of subjects: 24
Study 22933048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 19427263 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 36
Study 19427263 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 36
Study 17540198 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamet stent
Number of subjects: 120
Study 17540198 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 120
Study 15809124 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 210
Study 15809124 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 210
Study 15809124 — intervention group
Group type: COMPARATOR
Intervention: Combination of GA and EA (CA)
Number of subjects: 210
Study 12136612 — intervention group
Group type: EXPERIMENTAL
Intervention: K+ channel blockers
Number of subjects: 0
Study 12136612 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional anti‐arrhythmic drugs
Number of subjects: 0
Study 12136612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐arrhythmic drug selection
Number of subjects: 0
Study 12136612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐arrhythmic treatment
Number of subjects: 0
Study 10440638 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metronidazole administered at 8-hour intervals for 1 week
Number of subjects: 64
Study 10440638 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 8-hour intervals for 1 week
Number of subjects: 64
Study 10440638 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg metronidazole
Number of subjects: 64
Study 10440638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7767709 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal hygienic treatment (n = 11 after treatment)
Number of subjects: 20
Study 7767709 — intervention group
Group type: EXPERIMENTAL
Intervention: Before treatment (n = 9)
Number of subjects: 20
Study 7767709 — intervention group
Group type: COMPARATOR
Intervention: Healthy gingival samples (control group, n = 4)
Number of subjects: 20
Study 2181860 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmol Mg aspartate (20 mmol elemental Mg twice daily)
Number of subjects: 13
Study 2181860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7365607 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion groups with a nurse co-ordinator and a veteran mother, held for seven to ten weeks.
Number of subjects: 57
Study 31981597 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 74
Study 31981597 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 74
Study 31461138 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP (4 U bolus, then ≤0.04 U/min for 48 hours)
Number of subjects: 100
Study 31461138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31461138 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 100
Study 28064343 — intervention group
Group type: EXPERIMENTAL
Intervention: VisQ method (quantitative interpretation)
Number of subjects: 80
Study 28064343 — intervention group
Group type: COMPARATOR
Intervention: VisVis control (visual read only)
Number of subjects: 80
Study 26366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy (CBT)
Number of subjects: 100
Study 26366886 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study 23489638 — intervention group
Group type: EXPERIMENTAL
Intervention: Body and Soul program
Number of subjects: 8
Study 23489638 — intervention group
Group type: COMPARATOR
Intervention: Colon cancer screening intervention
Number of subjects: 8
Study 21094572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid prototyping (RP) for TMJ surgery
Number of subjects: 11